Consonance Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Consonance Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-790,197	Closed	-$25M	–	35
2021 Q1	$25M	Sell	790,197 -920,606	-54%	-$38.2M	2.67%	16
2020 Q4	$79.4M	Buy	+1,710,803	New	+$67.9M	7.41%	2
2020 Q1	–	Sell	-1,509,327	Closed	-$41.8M	–	35
2019 Q4	$41.8M	Sell	1,509,327 -170,000	-10%	-$3.87M	2.55%	17
2019 Q3	$30.6M	Sell	1,679,327 -4,173,509	-71%	-$92.3M	3.02%	14
2019 Q2	$144M	Buy	5,852,836 +4,712,836	+413%	+$71M	10.16%	3
2019 Q1	$10.8M	Buy	+1,140,000	New	+$11.1M	0.68%	23
2018 Q2	–	Sell	-3,206,073	Closed	-$54.2M	–	31
2018 Q1	$54.2M	Buy	3,206,073 +2,973,677	+1,280%	+$45M	4.95%	9
2017 Q4	$1.86M	Buy	+232,396	New	+$1.87M	0.17%	22

Other funds holding IOVA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Consonance Capital Management's IOVA Position: Q2 2021 in Review

Consonance Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2021, closing a stake of 790,197 shares — an estimated $25M sold.

Consonance Capital Management first reported a position in IOVA in Q4 2017 and held it in 8 quarters. The position peaked at $144M in Q2 2019. 233 funds tracked by Wall St. Rank hold IOVA as of Q2 2021.

Consonance Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2021 after selling out during the quarter.
Consonance Capital Management sold 790,197 Iovance Biotherapeutics shares in Q2 2021, an estimated $25M.
Consonance Capital Management first reported a position in Iovance Biotherapeutics in Q4 2017 and held it in 8 quarters.
Consonance Capital Management's Iovance Biotherapeutics position peaked at $144M in Q2 2019.
233 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2021.

Based on Consonance Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.